European Primary Care Cardiovascular Society
BP responses to exercise are similar in treated–controlled, treated-uncontrolled, and untreated hypertensives but higher compared with normotensives.
Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension
Before publication later this year, a first look at the new 2018 ESC/ESH Guidelines of hypertension was presented. One of the key messages was the unchanged definition of hypertension of BP >140/90 mmHg.
CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.
Both baseline and lifetime alcohol intake were inversely associated with the risk of non-fatal CHD, and positively associated with the risk of ischemic and hemorrhagic stroke.
No consistent benefit was seen of popular supplements (multivitamins, vitamin D, calcium and vitamin C) for the prevention of CVD, myocardial infarction or stroke, or on all-cause mortality.
EPCCS 2018 This is a brief version of the presentation that dr. Ramos gave on peripheral artery disease and associated risks and how it can best be managed.
Patients with a transient ischemic attack or minor stroke had a sustained elevated risk of CV events up to 5 years after the first event, and approximately half of these events occurred after the first year.
Results from the PIONEER 2 trial in T2DM patients demonstrated a significant and superior improvement in HbA1c with semaglutide compared to empagliflozin.
ESC 2018 In this debate, it became clear that not all are convinced yet about the use of the new ejection fraction category HFmrEF that was introduced in the latest ESC HF Guidelines in 2016.
ESC HF 2018 A network meta-analysis showed that incremental use of disease-modifying therapies lowers hospitalisations and mortality, which supports guideline recommendations.
ESC HF 2018 SwedeHF data show that RASi is associated with reduced morbidity and mortality in HF patients of 80 years and older. Absolute risk reduction is larger than in younger HF patients.
